KIM MCKINNON: Open Payments
NPI 1003302548 · SANDY, UT. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$804 in 41 payments from 15 companies in 2025. Trend: 2023 $1,626 · 2024 $1,503 · 2025 $804
Food & beverage: $804
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 15 | $265 |
| Neurocrine BioSciences, Inc. | 4 | $82 |
| Janssen Pharmaceuticals, Inc | 3 | $68 |
| Alkermes, Inc. | 2 | $53 |
| Axsome Therapeutics, Inc. | 2 | $51 |
| E.R. Squibb & Sons, L.L.C. | 3 | $51 |
| Tris Pharma Inc | 2 | $43 |
| Lundbeck LLC | 2 | $38 |
| Vanda Pharmaceuticals Inc. | 1 | $36 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 2 | $32 |
Products named: VRAYLAR, INGREZZA, ARISTADA, Auvelity, COBENFY, SPRAVATO, Dyanavel XR, REXULTI.
Industry payments across UT — which companies pay providers there.
